Direkt zum Inhalt
Merck

133M-1

Sigma-Aldrich

CD33 (PWS44) Mouse Monoclonal Antibody

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

UNSPSC-Code:
12352203
NACRES:
NA.41

Biologische Quelle

mouse

Qualitätsniveau

100
500

Konjugat

unconjugated

Antikörperform

culture supernatant

Antikörper-Produkttyp

primary antibodies

Klon

PWS44, monoclonal

Beschreibung

For In Vitro Diagnostic Use in Select Regions (See Chart)

Form

buffered aqueous solution

Speziesreaktivität

human

Verpackung

vial of 0.1 mL concentrate (133M-14)
vial of 0.5 mL concentrate (133M-15)
bottle of 1.0 mL predilute (133M-17)
vial of 1.0 mL concentrate (133M-16)
bottle of 7.0 mL predilute (133M-18)

Hersteller/Markenname

Cell Marque

Methode(n)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:20-1:80

Isotyp

IgG2b

Kontrolle

acute myeloid leukemia with monocytic

Versandbedingung

wet ice

Lagertemp.

2-8°C

Visualisierung

membranous

Angaben zum Gen

human ... CD33(945)

Allgemeine Beschreibung

CD33 (gp67, or siglec-3) is a 67 kDa glycosylated transmembrane protein that is a member of the sialic acid-binding immunoglobulin-like lectin (siglec) family. The genomic locus of this protein has been mapped to chromosome 1 9q1 3.1-3.5. In maturing granulocytic cells, there is progressive down-regulation of CD33 from the blast stage to mature neutrophils. However, in monocytes and macrophages/histiocytes, strong expression of CD33 is maintained throughout maturation. Therefore, the positive control tissue should be bone marrow myeloid cells (especially myeloid precursors), liver Kupffer cells, lung alveolar macrophages, or placental syncytiotrophoblasts. Detection of CD33 using monoclonal antibodies has been a critical component in immunophenotyping acute leukemias, particularly acute myeloid leukemias. This anti-CD33 may be particularly advantageous for cases of acute myeloid leukemia, minimally differentiated (AML-M0) and acute monocytic leukemia (AML-M5), in which other paraffin section markers of myeloid differentiation (such as anti-myeloperoxidase) may be negative. However, anti-CD33 staining cannot be used in isolation and must be correlated with other myeloid and lymphoid markers because cases of myeloid antigen-positive acute lymphoblastic leukemia may show bona fide CD33 expression. In characterizing a blast population, this antibody seems to be most useful when the percentage of blasts is high, such as in acute leukemias. It is not a helpful marker in estimating the percentage of blasts, such as in myelodysplastic syndromes or chronic myeloproliferative disorders, because other early granulocytic precursors such as promyelocytes and myelocytes will also stain with anti-CD33. Acute myeloid leukemias that involve extramedullary tissues frequently have monocytic differentiation. A definitive immunophenotype is often difficult to obtain because these cases may be negative or only focally positive for myeloperoxidase, and the currently available monocytic markers (anti-CD68 and anti-lysozyme) have limited specificity. All cases of myeloid sarcoma in this study showed anti-CD33 positivity in the myeloid and monocytic subsets, allowing for easy interpretation. The excellent sensitivity and specificity for myelomonocytic lineage makes this anti-CD33 a useful diagnostic marker for myeloid sarcoma. In addition, this anti-CD33 may be useful in determining CD33 expression on previous paraffin-embedded material if flow cytometry studies were not initially performed in patients with acute leukemia. Analysis of CD33 expression in paraffin-embedded bone marrow biopsy specimens provides another alternative when evaluating acute leukemias.

Qualität


IVD

IVD

IVD

RUO

Physikalische Form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Angaben zur Herstellung

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Sonstige Hinweise

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Rechtliche Hinweise

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Lagerklassenschlüssel

12 - Non Combustible Liquids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kylie D Mason et al.
Blood reviews, 20(2), 71-82 (2005-09-28)
Immunophenotyping of acute myeloid leukemia has controversial implications with regards to prognosis. Many associations have been described between individual antigen expression on myeloid blasts and prognosis, however few are consistent. Markers with a consistent prognostic association that have been demonstrated
Paul R Crocker et al.
Biochemical Society symposium, (69)(69), 83-94 (2003-03-27)
Siglecs are sialic-acid-binding proteins of the Ig superfamily that are involved in cell-cell interactions and signalling. In recent years, several novel siglecs that are highly related to CD33/Siglec-2 have been identified through genomics and functional screens. In addition to their
R C Braylan et al.
Cytometry, 46(1), 23-27 (2001-03-10)
At the ISAC 2000 Congress, the Clinical Cytometry Society organized a meeting of international experts to reach consensus on the minimum number of antibodies required for a full evaluation of hematologic and lymphoid neoplasias. A questionnaire was distributed prior to
Hong Chang et al.
Leukemia research, 28(1), 43-48 (2003-11-25)
We investigated the prognostic relevance of immunophenotype and other clinical pathological features in 379 adult patients with de novo (acute myeloid leukemia) AML diagnosed and treated at our institution during an 8-year period. Acute promyelocytic leukemia (APL) cases were excluded

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.